MARKET

ALVR

ALVR

Allovir, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

42.69
-2.35
-5.22%
Pre Market: 42.99 +0.3 +0.70% 08:08 01/25 EST
OPEN
44.46
PREV CLOSE
45.04
HIGH
44.46
LOW
40.73
VOLUME
300
TURNOVER
--
52 WEEK HIGH
48.96
52 WEEK LOW
18.15
MARKET CAP
2.61B
P/E (TTM)
-96.3222
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Ce...
Business Wire · 01/11 18:52
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Ce...
BusinessWire · 01/11 15:52
AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.
Business Wire · 01/04 12:30
AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.
BusinessWire · 01/04 09:30
Have Insiders Been Buying AlloVir, Inc. (NASDAQ:ALVR) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Simply Wall St. · 12/29/2020 04:21
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
FDA clears AlloVir's ALVR106 application in respiratory viruses
The FDA has cleared AlloVir's (ALVR) Investigational New Drug ((IND)) application for ALVR106, an allogeneic, off-the-shelf virus-specific T cell therapy designed to target infections and diseases caused by respiratory syncytial
Seekingalpha · 12/17/2020 12:48
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses
Proof-of-concept phase 1/2 trial to initiate in 2021 to treat severe respiratory viral infections in patients following hematopoietic stem cell transplantation ALVR106 designed to target devastating diseases caused by
Benzinga · 12/17/2020 12:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALVR. Analyze the recent business situations of Allovir, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALVR stock price target is 46.50 with a high estimate of 52.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 20.87M
% Owned: 34.13%
Shares Outstanding: 61.17M
TypeInstitutionsShares
Increased
0
0
New
60
20.87M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Chief Executive Officer/Director
David Hallal
President/Chief Financial Officer/Director
Vikas Sinha
Co-Founder/Chief Scientific Officer
Ann Leen
Chief Accounting Officer
Brett Hagen
General Counsel
Edward Miller
General Manager
Ugo Capolino Perlingieri
Executive Officer
Jeroen van Beek
Executive Officer
Jeroen Van Beek
Other
Ercem Atillasoy
Other
Agustin Melian
Director
Juan Vera
Independent Director
Jeffrey Bornstein
Independent Director
Diana Brainard
Independent Director
Malcolm Brenner
Independent Director
Ansbert Gadicke
Independent Director
Morana Jovan-Embiricos
Independent Director
John Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALVR
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).
More

Webull offers kinds of Allovir Inc stock information, including NASDAQ:ALVR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALVR stock methods without spending real money on the virtual paper trading platform.